Document Detail


Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
MedLine Citation:
PMID:  22725705     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Tadalafil distinguishes itself from other available phosphodiesterase type 5 (PDE-5) inhibitors by its half-life of ∼ 17.5 h, which results in erectile responsiveness for up to 36 h after a single dose. Most clinical experience has been reported with on-demand use of PDE-5 inhibitors, but several studies have been able to demonstrate that tadalafil, given once-daily in low doses, is both highly effective and well tolerated.
AREAS COVERED: This paper reviews the current evidence for efficacy and safety of tadalafil, as well as the rationale for offering low-dose tadalafil once-daily to patients with erectile dysfunction as an alternative to on-demand treatment.
EXPERT OPINION: Tadalafil once-daily provides efficacy comparable to on-demand dosing regimens with PDE-5 inhibitors, is well tolerated and allows patients and their partners to disconnect the administration of medication from sexual activity, thereby enabling them to return to the sex-life they had before the onset of erectile dysfunction.
Authors:
Hartmut Porst; Katja Hell-Momeni; Hartwig Büttner
Related Documents :
19714525 - Dose prescription and optimisation based on tumour hypoxia.
9876375 - Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with a...
22724555 - Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects.
8713695 - Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent ...
19231105 - Dosimetric effect of prostate motion during helical tomotherapy.
1097195 - Preliminary clinical experience with meptazinol, a new analgesic.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-25     Completed Date:  2012-11-20     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1481-94     Citation Subset:  IM    
Affiliation:
Urology and Andrology Center, Neuer Jungfernstieg 6a, 20354 Hamburg, Germany. Porst20354@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carbolines / administration & dosage*,  adverse effects,  pharmacokinetics
Drug Administration Schedule
Erectile Dysfunction / drug therapy*,  physiopathology
Humans
Male
Phosphodiesterase 5 Inhibitors / administration & dosage*,  adverse effects,  pharmacokinetics
Chemical
Reg. No./Substance:
0/Carbolines; 0/Phosphodiesterase 5 Inhibitors; 0/tadalafil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin a...
Next Document:  Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy.